| 000 | 01871 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515162516.0 | ||
| 264 | 0 | _c20090416 | |
| 008 | 200904s 0 0 eng d | ||
| 022 | _a1078-0432 | ||
| 024 | 7 |
_a10.1158/1078-0432.CCR-08-2663 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDavis, Ian D | |
| 245 | 0 | 0 |
_aClinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. _h[electronic resource] |
| 260 |
_bClinical cancer research : an official journal of the American Association for Cancer Research _cMar 2009 |
||
| 300 |
_a2123-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterleukin-2 Receptor alpha Subunit _xblood |
| 650 | 0 | 4 |
_aInterleukins _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aRecombinant Proteins _xtherapeutic use |
| 650 | 0 | 4 |
_aT-Lymphocyte Subsets _ximmunology |
| 650 | 0 | 4 | _aInterleukin-21 |
| 700 | 1 | _aBrady, Ben | |
| 700 | 1 | _aKefford, Richard F | |
| 700 | 1 | _aMillward, Michael | |
| 700 | 1 | _aCebon, Jonathan | |
| 700 | 1 | _aSkrumsager, Birte K | |
| 700 | 1 | _aMouritzen, Ulrik | |
| 700 | 1 | _aHansen, Lasse Tengbjerg | |
| 700 | 1 | _aSkak, Kresten | |
| 700 | 1 | _aLundsgaard, Dorthe | |
| 700 | 1 | _aFrederiksen, Klaus Stensgaard | |
| 700 | 1 | _aKristjansen, Paul E G | |
| 700 | 1 | _aMcArthur, Grant | |
| 773 | 0 |
_tClinical cancer research : an official journal of the American Association for Cancer Research _gvol. 15 _gno. 6 _gp. 2123-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1078-0432.CCR-08-2663 _zAvailable from publisher's website |
| 999 |
_c18715994 _d18715994 |
||